Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohortAndrea Serafin, Andrea Visentin, Monia Marchetti et al.|Blood Advances|2025Cited by 3
Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.Luca Laurenti, Idanna Innocenti, Antonio Mosca et al.|Blood|2025Cited by 0
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive studyAndrea Visentin, Giuseppe Petruzzellis, Thomas Chatzikonstantinou et al.|Blood|2025Cited by 0